About ABiC

Based on the same principles as angioplasty, ABiC™ uses breakthrough microcatheter technology to enlarge your eye’s natural drainage system, improving outflow and lowering intraocular pressure. It can also free you from the financial and lifestyle burdens of glaucoma medications. It is important to note that ABiC™ acts to restore the eye’s natural outflow system and does not require a permanent implant or device in your eye.

  • Restorative treatment of eye’s natural drainage system
  • Sustained reduction of pressure in the eye
  • Reduced dependence on expensive medications
  • Minimally invasive for quicker recovery and return to daily activities
  • Limited risk of complications versus traditional surgical alternatives
  • No need for a permanent implant or device in your eye
  • No limitations on your favorite activities

First, your surgeon will make a small incision in the eye. A microcatheter designed specifically for ABiC™ is then inserted into the eye’s circumferential drainage canal, which may be reduced in size or closed due to the high pressure in your eye. Your surgeon will advance the microcatheter 360 degrees around the canal to open up the channel and enlarge it. Once the end of the catheter has circumnavigated to its point of entry, the microcatheter tip is slowly pulled back while sterile, viscoelastic gel is injected into the canal to dilate it to 2-3 times its normal size. Enlarging and flushing through the drainage canal and adjacent outflow channels helps the aqueous fluid to drain properly. The microcatheter is then withdrawn from the eye. It is important to note that there are no permanent implants or devices left in the eye.

By restoring your eye’s natural drainage system, the pressure inside your eye is usually lowered.

One to three days after the procedure, your intraocular pressure should drop significantly. And of course, your physician will want to re-check the treated eye during periodic follow-up visits.

No. During the surgery your eye will be anesthetized. Post-surgery your surgeon will prescribe eye drops to reduce inflammation and to prevent pain.

It is necessary to first undergo an ophthalmic examination to determine your eligibility for ABiC™. ABiC™ is an effective surgical option for the majority of glaucoma patients. If you fit into any of the following categories, you’re a good candidate for ABiC™:

  • If you have primary open-angle, pseudoexfoliation, or pigmentary glaucoma. (If you’re not sure, ask your ophthalmologist.)
  • If you are intolerant of glaucoma medications, or have difficulty taking them as prescribed.
  • If you are about to have cataract surgery and wish to use this opportunity to reduce the number of glaucoma medications you are currently taking.
  • If it is difficult for you to commit to regular follow-up treatments, due to finances, lack of transportation, or other limitations.
  • If you have a history of failed ALT (argon laser trabeculoplasty) treatments.
  • ABiC™ is also suitable for patients who wear contact lenses. Patients with contact lenses are unable to undergo the traditional forms of glaucoma surgery (trabeculectomy or shunt).

Please note that ABiC™ is not suitable for patients with neovascular or chronic angle-closure glaucoma.

One of the key advantages of ABiC™ is its high safety profile. It is associated with significantly fewer risks, both in number and severity, than traditional glaucoma surgeries. It is important to note, however, that all surgeries have risks associated with them. The most common risks associated with ABiC™ are:

  • Bleeding in the Eye
  • Intraocular Pressure “Spikes”
  • The Formation of a Bleb
  • Hypotony (IOP too low)

A key benefit of ABiC™ is that is does not preclude any other form of glaucoma treatment. If the procedure is not successful, your surgeon may elect to perform laser-based treatment, such as SLT, or conventional glaucoma surgery (trabeculectomy). Medication may also be an option.

“Rather than trying to mechanically change or bypass the pathway of aqueous outflow, ABiC acts to restore the natural outflow process by targeting all aspects of the outflow system. That is, the trabecular meshwork, Schlemm canal, and the collector channels.”
Mark J. Gallardo, MD
El Paso Eye Surgeons, Texas, USA

ABiC Patient Spotlight

46-year-old Leon McClinton was devastated when he was told by his doctor that he would go blind in one eye, and there was nothing he could do about it.

Leon’s colleague urged him to get a second opinion at Dean McGee Eye Institute. Thanks to Dr. Mahmoud A. Khaimi and ABiC™ – a revolutionary MIGS procedure, Leon is now able to see the world with restored vision and hope.

Watch Leon’s story here: